KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
89 hedge funds and large institutions have $364M invested in KalVista Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 19 closing their positions.
16% more capital invested
Capital invested by funds: $315M → $364M (+$49.2M)
11% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 28
1.96% more ownership
Funds ownership: 97.2% → 99.16% (+2%)
8% less funds holding
Funds holding: 97 → 89 (-8)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.31M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.64M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.15M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$3.3M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$17.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.68M |
| 3 |
DM
Deerfield Management
New York
|
-$4.95M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.18M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.84M |
KALV Hedge Fund Activity: Q1 2022 in Review
89 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2022, worth a combined $364M — up 16% from $315M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KALV and 11 opened new positions — a net loss of 8 holders — while 28 trimmed existing stakes and 31 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.31M. The largest seller was Frazier Management, exiting entirely with an estimated $17.3M sold.
- 89 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2022, down from 97 in Q4 2021.
- Funds reported $364M of KalVista Pharmaceuticals stock for Q1 2022, up 16% quarter-over-quarter.
- 11 funds opened new KalVista Pharmaceuticals positions in Q1 2022 and 19 closed out, a net change of -8 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2022 was Tang Capital Management, an estimated $9.31M added.
- The largest KalVista Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2022.